The addition of pembrolizumab to standard platinum-pemetrexed chemotherapy results in significant improvement in overall survival among patients with advanced pleural mesothelioma, according to a study published online Nov. ...
Nov 15, 2023
0
0
For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, according to a study presented at the annual ...
Apr 8, 2024
0
0
New research in the December 2023 issue of Journal of the National Comprehensive Cancer Network finds that patients treated with first-line immunotherapy for advanced non-small cell lung cancer (NSCLC) showed similar results ...
Dec 11, 2023
0
0
Early improvements in cardiac and hematologic parameters may predict better survival outcomes for patients being treated for stage IIIb AL amyloidosis, a deadly disease with a median survival of four to six months caused ...
Aug 15, 2023
0
4
The use of circulating tumor cell (CTC) count to guide the choice between chemotherapy and endocrine therapy as first-line therapy for patients with metastatic, estrogen receptor (ER)-positive/HER2-negative breast cancer ...
Dec 8, 2022
0
2
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal ...
Apr 8, 2024
0
0
Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at the annual hybrid congress ...
Jun 26, 2024
0
0
Among men with very high-risk prostate cancer, higher radiation facility case volume is independently associated with longer overall survival, according to a study published online Aug. 8 in JAMA Network Open.
Aug 16, 2023
0
1
